Cipla Ltd

- FY’26 EBITDA margin expected to land around 21%, slightly affected by lower-than-anticipated Lanreotide sales and the end of generic Revlimid billing cycle. - Planned investments in R&D, manufacturing, and talent to support new launches and pipeline readiness expected to continue. - R&D spend anticipated around 5-6% of revenue, with some quarterly lumpiness depending on project timelines. - FY’27 margin guidance not yet provided; to be shared post annual operating plan finalization. - New product launches, including four peptides and respiratory assets in the US, are key drivers for sustainable longer-term growth. - Expected resumption of Lanreotide supply in H1 FY’27 anticipated to stabilize US business. - Trade and branded generics in India expected to maintain growth momentum; no significant impact expected from Schedule M implementation. - Continuous cost optimization programs underway to improve operating efficiency.

The provided transcript of Cipla Limited's Q3 FY26 earnings call dated January 23, 2026, does not explicitly mention details regarding the current or expected order book or pending orders. The discussion primarily focuses on: - Product launches and pipeline updates including peptides and respiratory assets. - Market performance in different regions such as the US, South Africa, and EMEU. - Operational aspects like Schedule M implementation and manufacturing facility inspections. - Financial details including exceptional items, R&D expenses, gross margin impacts, and capital commitments. No specific quantification or commentary on order book size or pending orders was provided during the call or in the accompanying document.

- There is no explicit mention of any current or future fundraising through debt or equity in the provided transcript. - As of December 31, 2025, Cipla reported a net cash position of Rs. 10,229 crores after adjusting for dividends and payments related to Galvus. - The company’s outstanding debt, including lease liabilities, stood at Rs. 489 crores, indicating a low debt level. - No specific plans or guidance were provided regarding raising capital via debt or equity in the near future. - The focus appears to be on growth through internal operations, R&D investments, and upcoming product launches rather than external fundraising.

- Recent capital commitment of Rs. 1,100 crores related to the Galvus perpetual license and in-house manufacturing (Page 20). - Ongoing investments in manufacturing derisking and readiness for upcoming product launches, including US facilities (Pages 5, 16). - Minor capital expenses include lab equipment purchases (Page 16). - Continuous improvement programs focused on cost optimization and operating overhead pruning underway, expected to yield benefits starting next year (Page 16). - No specific forward-looking capex guidance disclosed yet; FY’27 annual operating plan is in progress (Page 9). - Discussions on setting up a second manufacturing site for Lanreotide (not in the same market) to derisk supply (Page 12).

- Upcoming launches in the US (including four significant respiratory launches and generic Victoza) are expected to drive sustainable long-term growth and help cushion decline from legacy products like Lenalidomide. - One-India business showed strong 10% YoY growth, with a focus on execution to sustain momentum and outperform the market in both branded and trade generics. - Chronic therapies like diabetes, cardiac, respiratory, and urology are key growth drivers. - Expansion in consumer health with leading brands and distribution growth. - In EMEU, sustained growth with over $100 million quarterly revenue and margin stability. - South Africa private market showing strong secondary growth of 6.3%, with normalization expected post channel destocking. - R&D investments and new product pipelines (e.g., peptides and respiratory assets) position Cipla for volume and revenue growth. - Evaluating alternate manufacturing sites to mitigate supply disruptions and support future sales continuity.